Literature DB >> 9847337

Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells.

I V Redchenko1, A B Rickinson.   

Abstract

The conventional means of studying Epstein-Barr virus (EBV)-induced cytotoxic T-lymphocyte (CTL) memory, by in vitro stimulation with the latently infected autologous lymphoblastoid cell line (LCL), has important limitations. First, it gives no information on memory to lytic cycle antigens; second, it preferentially amplifies the dominant components of latent antigen-specific memory at the expense of key subdominant reactivities. Here we describe an alternative approach, based on in vitro stimulation with epitope peptide-loaded dendritic cells (DCs), which allows one to probe the CTL repertoire for any individual reactivity of choice; this method proved significantly more efficient than stimulation with peptide alone. Using this approach we first show that reactivities to the immunodominant and subdominant lytic cycle epitopes identified by T cells during primary EBV infection are regularly detectable in the CTL memory of virus carriers; this implies that in such carriers chronic virus replication remains under direct T-cell control. We further show that subdominant latent cycle reactivities to epitopes in the latent membrane protein LMP2, though rarely undetectable in LCL-stimulated populations, can be reactivated by DC stimulation and selectively expanded as polyclonal CTL lines; the adoptive transfer of such preparations may be of value in targeting certain EBV-positive malignancies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9847337      PMCID: PMC103838     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily.

Authors:  L J Zhou; R Schwarting; H M Smith; T F Tedder
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

2.  Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients.

Authors:  J W Gratama; M M Zutter; J Minarovits; M A Oosterveer; E D Thomas; G Klein; I Ernberg
Journal:  Int J Cancer       Date:  1991-01-21       Impact factor: 7.396

3.  In vitro human cytotoxic T cell responses against influenza A virus can be induced and selected by synthetic peptides.

Authors:  F Martinon; E Gomard; C Hannoun; J P Lévy
Journal:  Eur J Immunol       Date:  1990-10       Impact factor: 5.532

4.  Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells.

Authors:  S E Macatonia; S Patterson; S C Knight
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

5.  GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.

Authors:  C Caux; C Dezutter-Dambuyant; D Schmitt; J Banchereau
Journal:  Nature       Date:  1992-11-19       Impact factor: 49.962

6.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.

Authors:  R Khanna; S R Burrows; M G Kurilla; C A Jacob; I S Misko; T B Sculley; E Kieff; D J Moss
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

7.  Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.

Authors:  J M Brooks; R J Murray; W A Thomas; M G Kurilla; A B Rickinson
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

8.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.

Authors:  R J Murray; M G Kurilla; J M Brooks; W A Thomas; M Rowe; E Kieff; A B Rickinson
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

9.  Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo.

Authors:  K Inaba; M Inaba; M Naito; R M Steinman
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  14 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.

Authors:  Lisa A Jurgens; Rajiv Khanna; James Weber; Rimas J Orentas
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

3.  A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma.

Authors:  Rajeev K Tyagi; Rajesh Parmar; Naisargee Patel
Journal:  Hum Vaccin Immunother       Date:  2016-11-30       Impact factor: 3.452

4.  Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice.

Authors:  R G Caldwell; R C Brown; R Longnecker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A.

Authors:  Yingchun Yan; Qing-Jie Xue; Ang Liu; Hui Wang; Honghua Zhang; Shuang Wang; Longyu Zhao; Yunqing Li; Xiuzhen Li; Yuanyuan Yang; Ting Chen; Shigen Li
Journal:  Hum Vaccin Immunother       Date:  2019-10-29       Impact factor: 3.452

6.  Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.

Authors:  E Ranieri; W Herr; A Gambotto; W Olson; D Rowe; P D Robbins; L S Kierstead; S C Watkins; L Gesualdo; W J Storkus
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms.

Authors:  Na Cheng; Da-yang Hui; Yong Liu; Na-na Zhang; Ye Jiang; Jing Han; Hai-Gang Li; Yun-Gang Ding; Hong Du; Jian-Ning Chen; Chun-Kui Shao
Journal:  Gastric Cancer       Date:  2014-04-27       Impact factor: 7.370

8.  Efficacy of recombinant adenovirus expressing a fusion gene from GM-CSF and Epstein-Barr virus LMP2A in a mouse tumor model.

Authors:  Qingjie Xue; Xiuzhen Li; Chunqing Yang; Bingyuan Ji; Yunqing Li; Yingchun Yan; Xinxin Yang; Chunmei Wang; Ting Chen
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

9.  Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.

Authors:  G S Taylor; T A Haigh; N H Gudgeon; R J Phelps; S P Lee; N M Steven; A B Rickinson
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Professional antigen presenting cells in human herpesvirus 8 infection.

Authors:  Emilee R Knowlton; Lauren M Lepone; Jun Li; Giovanna Rappocciolo; Frank J Jenkins; Charles R Rinaldo
Journal:  Front Immunol       Date:  2013-01-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.